A 28-Day Parallel Group Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)
Completed
Theravance Biopharma
Phase 2
2014-05-01
This study evaluated the safety and efficacy of four doses of TD-4208 and a placebo product
when administered once daily for 28 days using a jet nebulizer to patients with moderate to
severe chronic obstructive pulmonary disease.
A 28-Day Parallel Group Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)
Completed
Mylan Inc.
Phase 2
2014-05-01
This study evaluated the safety and efficacy of four doses of TD-4208 and a placebo product
when administered once daily for 28 days using a jet nebulizer to patients with moderate to
severe chronic obstructive pulmonary disease.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
